People · Operator
Named in public records as an officer, director or promoter · active 2015–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juventas Therapeutics Inc | — | Biotechnology | Series B | $35.8M | $52.0M | 2015 |
James Boland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Boland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Somu Subramaniam | 1 | 17 |
| George Arida | 1 | 6 |
| Linda Tufts | 1 | 5 |
| George Emont | 1 | 4 |
| Marc Penn | 1 | 4 |
| Roger Newton | 1 | 4 |
| Suzette Dutch | 1 | 3 |
| Troy Ignelzi | 1 | 3 |
| Rahul Aras | 1 | 3 |
| Jack Miner | 1 | 1 |
| Matthew Pollman | 1 | 1 |
| Matt Pollman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.